Research Article
Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX
Table 2
Patient characteristics.
| Parameters | FOLFOX4 | FOLFOX6 | mFOLFOX6 | FOLFOX7 | No. of patients | % | No. of patients | % | No. of patients | % | No. of patients | % |
| Gender | | | | | | | | | Male | 10 | 76.92 | 9 | 75 | 4 | 80 | 6 | 75 | Female | 3 | 23.08 | 3 | 25 | 1 | 20 | 2 | 25 | Age: year | | | | | | | | | Median | 63 | | 60 | | 51 | | 67 | | Range | 58–64 | | 52–68 | | 47–53 | | 49–72 | | ECOG performance status | | | | | | | | | 0 | 1 | 7.69 | 1 | 8.33 | 0 | 0 | 0 | 0 | 1 | 4 | 30.77 | 1 | 8.33 | 3 | 60 | 2 | 25 | 2 | 7 | 53.85 | 10 | 83.33 | 2 | 40 | 5 | 62.5 | 3 | 1 | 7.69 | 0 | 0 | 0 | 0 | 1 | 12.5 | Primary site | | | | | | | | | Colon | 10 | 76.92 | 7 | 58.33 | 2 | 40 | 3 | 37.5 | Rectum | 3 | 23.08 | 5 | 41.67 | 1 | 20 | 2 | 25 | Multiple | 0 | 0 | 0 | 0 | 2 | 40 | 3 | 37.5 | No. of sites | | | | | | | | | 1 | 7 | 53.85 | 4 | 33.33 | 3 | 60 | 6 | 75 | ≥2 | 6 | 46.15 | 8 | 66.67 | 2 | 40 | 2 | 25 | AlkPO4 | | | | | | | | | Normal | 3 | 23.08 | 6 | 50 | 3 | 60 | 5 | 62.5 | Increased | 7 | 53.85 | 3 | 25 | 2 | 40 | 3 | 37.5 | Unknown | 3 | 23.08 | 3 | 25 | 0 | 0 | 0 | 0 |
|
|